{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:17:51Z","timestamp":1794601071744,"version":"4.9.1"},"reference-count":80,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PRA"],"published-print":{"date-parts":[[2020,12,7]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Maintenance chemotherapeutic regimen with low toxicity is needed for\nmetastatic colorectal cancer. A recent patent has been issued on the spleen-strengthening and detoxification\nprescription (JPJDF), a traditional Chinese herbal medicinal formula with anti-angiogenesis\neffect. The clinical effect of JPJDF on the maintenance treatment of advanced colorectal cancer\nhas not been evaluated.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study aims to evaluate the effectiveness and safety of JPJDF in combination with\nfluoropyrimidine compared to fluoropyrimidine alone as maintenance therapy for metastatic colorectal\ncancer.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We applied a prospective, randomized, double-blinded, single center clinical study design.\nA total of 137 patients with advanced colorectal cancer were recruited. Patients received either\nFluoropyrimidine (Flu-treated group, n = 68), or Fluoropyrimidine plus JPJDF (Flu-F-treated\ngroup, n = 69) as maintenance treatment after 6-cycle of FOLFOX4 or FOLFORI induction treatment.\nThe primary endpoints were Progression-Free Survival (PFS) and Overall Survival (OS).\nThe secondary endpoints were safety, Performance Status (PS) score and other symptoms.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The endpoint of disease progression was observed in 91.7% of patients. The PFS was 5.0\nmonths and 3.0 months in the Flu-F-treated and Flu-treated groups, respectively. The OS was 15.0\nmonths and 9.0 months in the Flu-F-treated and Flu-treated groups, respectively. Some common\nsymptoms, such as hypodynamia, anepithymia, dizziness and tinnitus and shortness of breath, were\nimproved in the Flu-F-treated group. There was no significant difference in the common adverse reactions\nbetween the two groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>JPJDF and fluoropyrimidine have synergistic effect in the maintenance treatment of\nmCRC.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574892815666200717141205","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T21:16:18Z","timestamp":1595020578000},"page":"257-269","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer"],"prefix":"10.2174","volume":"15","author":[{"given":"Xiaoling","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, No. 110, Ganhe Road, Shanghai 200437, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, No. 528, Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, No. 528, Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengcheng","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, No. 528, Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, No. 528, Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, No. 528, Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, No. 110, Ganhe Road, Shanghai 200437, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Surgery, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, No. 528, Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifen","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, No. 528, Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, No. 110, Ganhe Road, Shanghai 200437, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, No. 528, Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huirong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, No. 528, Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, No. 528, Zhangheng Road, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21147\/j.issn.1000-9604.2017.01.01","volume":"29","author":"Chen W.","year":"2017","unstructured":"Chen W.; Zheng R.; Zhang S.; Cancer incidence and mortality in China in 2013: An analysis based on urbanization level. Chin J Cancer Res 2017,29(1),1-10","journal-title":"Chin J Cancer Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.puhe.2020.01.021","volume":"182","author":"Sharma T.","year":"2020","unstructured":"Sharma T.; Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults. Public Health 2020,182,70-76","journal-title":"Public Health"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40880-017-0234-3","volume":"36","author":"Zheng R.","year":"2017","unstructured":"Zheng R.; Zeng H.; Zhang S.; Chen W.; Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer 2017,36(1),66","journal-title":"Chin J Cancer"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.3748\/wjg.v21.i17.5167","volume":"21","author":"Kim S.E.","year":"2015","unstructured":"Kim S.E.; Paik H.Y.; Yoon H.; Lee J.E.; Kim N.; Sung M.K.; Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol 2015,21(17),5167-5175","journal-title":"World J Gastroenterol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/jso.21404","volume":"100","author":"Tsai H.L.","year":"2009","unstructured":"Tsai H.L.; Chu K.S.; Huang Y.H.; Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol 2009,100(8),736-743","journal-title":"J Surg Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","volume":"27","author":"Chibaudel B.","year":"2009","unstructured":"Chibaudel B.; Maindrault-Goebel F.; Lledo G.; Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009,27(34),5727-5733","journal-title":"J Clin Oncol"},{"key":"ref=7","first-page":"11","volume":"63","author":"Siegel R.","year":"2013","unstructured":"Siegel R.; Naishadham D.; Jemal A.; Cancer statistics 2013 CA: A cancer journal for clinicians. ACS J 2013,63(1),11-30","journal-title":"ACS J"},{"key":"ref=8","first-page":"775","volume":"16","author":"Song S-P.","year":"2006","unstructured":"Song S-P.; Liu B.; Advanced in medical treatment of metastatic colorectal cancer. China Oncology 2006,16(10),775-780","journal-title":"China Oncology"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"e000605","DOI":"10.1136\/esmoopen-2019-000605","volume":"5","author":"You X.H.","year":"2020","unstructured":"You X.H.; Jiang Y.H.; Fang Z.; Sun F.; Li Y.; Wang W.; Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials. ESMO Open 2020,5(2),e000605","journal-title":"ESMO Open"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/bjc.2017.279","volume":"117","author":"Codony-Servat J.","year":"2017","unstructured":"Codony-Servat J.; Cuatrecasas M.; Asensio E.; Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. Br J Cancer 2017,117(12),1777-1786","journal-title":"Br J Cancer"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ctrv.2015.10.012","volume":"42","author":"Esin E.","year":"2016","unstructured":"Esin E.; Yalcin S.; Maintenance strategy in metastatic colorectal cancer: A systematic review. Cancer Treat Rev 2016,42,82-90","journal-title":"Cancer Treat Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41575-019-0189-8","volume":"16","author":"Keum N.","year":"2019","unstructured":"Keum N.; Giovannucci E.; Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol 2019,16(12),713-732","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=13","author":"Ferrara N","year":"2018","unstructured":"Ferrara N; Nina K; Robert MD; VEGF-specific antagonists for adjuvant therapy and neoadjuvant therapy, and treatment of early stage tumors. JP2018052939, 2018"},{"key":"ref=14","author":"Rajasekhar K","year":"2011","unstructured":"Rajasekhar K; Nariyam SM; Murki V; Preparation of capecitabine. US20110224422, 2011"},{"key":"ref=15","author":"Zhao Z","year":"2013","unstructured":"Zhao Z; Hao G; Liu A; Method for preparing tegafur, gimeracil and oteracil potassium capsules. CN103211820, 2013"},{"key":"ref=16","author":"Ge S","year":"2016","unstructured":"Ge S; Lin F; Huang J; Raltitrexed solvate and preparation method thereof. CN201611244886, 2016"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13063-020-4194-6","volume":"21","author":"Shi M.","year":"2020","unstructured":"Shi M.; Ma T.; Xi W.; A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer. Trials 2020,21(1),249","journal-title":"Trials"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/0959-8049(95)00487-4","volume":"31a","author":"Gonzalez-Baron M","year":"1995","unstructured":"Gonzalez-Baron M; Feliu J; de la Gandara I; Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. European J Cancer (Oxford, England: 1990) 1995,31a(13-14),2215-2219","journal-title":"European J Cancer (Oxford, England: 1990)"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1634\/theoncologist.2018-0901","volume":"24","author":"Chen Y.","year":"2019","unstructured":"Chen Y.; Wu J.; Cheng K.; S-1 plus raltitrexed for refractory metastatic colorectal cancer: A Phase II trial. Oncologist 2019,24(5),591-e165","journal-title":"Oncologist"},{"key":"ref=20","first-page":"774","author":"Lei Z.","year":"2014","unstructured":"Lei Z.; Qin L.; Maintenance therapy in patients with advanced colorectal cancer: Selection of optimal regimen. Zhongguo Yiyuan Yongyao Pingjia Yu Fenxi 2014(9),774-777","journal-title":"Zhongguo Yiyuan Yongyao Pingjia Yu Fenxi"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"6180810","DOI":"10.1155\/2018\/6180810","volume":"2018","author":"Zhang S","year":"2018","unstructured":"Zhang S; Shi L; Mao D; Use of Jianpi Jiedu herbs in patients with advanced colorectal cancer: a systematic review and meta-analysis. eCAM 2018,2018,6180810","journal-title":"eCAM"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ctim.2016.10.001","volume":"29","author":"Chien T.J.","year":"2016","unstructured":"Chien T.J.; Liu C.Y.; Lu R.H.; Kuo C.W.; Lin Y.C.; Hsu C.H.; Therapeutic efficacy of traditional Chinese medicine, \u201cKuan-Sin-Yin\u201d, in patients undergoing chemotherapy for advanced colon cancer - A controlled trial. Complement Ther Med 2016,29,204-212","journal-title":"Complement Ther Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10151-008-0392-z]","volume":"12","author":"Tan K.Y.","year":"2008","unstructured":"Tan K.Y.; Liu C.B.; Chen A.H.; Ding Y.J.; Jin H.Y.; Seow-Choen F.; The role of traditional Chinese medicine in colorectal cancer treatment. Tech Coloproctol 2008,12(1),1-6","journal-title":"Tech Coloproctol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5582\/bst.2015.01019","volume":"9","author":"Qi F.","year":"2015","unstructured":"Qi F.; Zhao L.; Zhou A.; The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends 2015,9(1),16-34","journal-title":"Biosci Trends"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"109570","DOI":"10.1016\/j.biopha.2019.109570","volume":"121","author":"Wang Y.","year":"2020","unstructured":"Wang Y.; Zhang Q.; Chen Y.; Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomed Pharmacother 2020,121,109570","journal-title":"Biomed Pharmacother"},{"key":"ref=26","first-page":"19","volume":"30","author":"Li-rong L.I.U.","year":"2014","unstructured":"Li-rong L.I.U.; Yan-juan Z.H.U.; Meta-analysis on efficacy and life quality of advanced colorectal cancer with Chinese medicine combined with chemotherapy. J Nanjing Univ TCM 2014,30(1),19-21","journal-title":"J Nanjing Univ TCM"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/jcpt.12410","volume":"41","author":"Ge L.","year":"2016","unstructured":"Ge L.; Wang Y.F.; Tian J.H.; Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer. J Clin Pharm Ther 2016,41(4),383-391","journal-title":"J Clin Pharm Ther"},{"key":"ref=28","first-page":"CD004653","author":"Guo Z.","year":"2012","unstructured":"Guo Z.; Jia X.; Liu J.P.; Liao J.; Yang Y.; Herbal medicines for advanced colorectal cancer. Cochrane Database Syst Rev 2012(5),CD004653","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1534735415617282","volume":"15","author":"Chien T.J.","year":"2016","unstructured":"Chien T.J.; Liu C.Y.; Ko P.H.; Hsu C.H.; A Chinese decoction, Kuan-sin-yin, improves autonomic function and cancer-related symptoms of metastatic colon cancer. Integr Cancer Ther 2016,15(1),113-123","journal-title":"Integr Cancer Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1038\/s41598-018-25500-x","volume":"8","author":"Zhu H.","year":"2018","unstructured":"Zhu H.; Hao J.; Niu Y.; Liu D.; Chen D.; Wu X.; Molecular targets of Chinese herbs: A clinical study of metastatic colorectal cancer based on network pharmacology. Sci Rep 2018,8(1),7238","journal-title":"Sci Rep"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11655-018-2980-0","volume":"24","author":"Zhang T.","year":"2018","unstructured":"Zhang T.; He W.T.; Zi M.J.; Song G.; Yi D.H.; Yang Y.F.; Cohort study on prognosis of patients with metastatic colorectal cancer treated with integrated Chinese and western medicine. Chin J Integr Med 2018,24(8),573-578","journal-title":"Chin J Integr Med"},{"key":"ref=32","author":"Li Q.","year":"2016","unstructured":"Li Q.; A compound preparation of traditional Chinese medicine for colorectal cancer and its preparation. CN201610118611, 2016"},{"key":"ref=33","first-page":"584","volume":"006","author":"Liu Guiwei.","year":"2015","unstructured":"Liu Guiwei.; Ma Xiaoqun.; Ren Weidan.; Treatment of advanced colorectal cancer with compound Chinese medicine combined with capecitabine. Jilin J Chin Med 2015,006,584-586","journal-title":"Jilin J Chin Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s11655-013-1452-4","volume":"20","author":"Sui H.","year":"2014","unstructured":"Sui H.; Zhu H.R.; Wu J.; Effects of Jianpi Jiedu Recipe on reversion of P-glycoprotein-mediated multidrug resistance through COX-2 pathway in colorectal cancer. Chin J Integr Med 2014,20(8),610-617","journal-title":"Chin J Integr Med"},{"key":"ref=35","first-page":"181","volume":"S1","author":"Jian S.","year":"2017","unstructured":"Jian S.; Yan W.; Qing J.; Hua S.; Jue Z.; Qi L.; Effects of Jianpi Jiedu recipe on expressions of DNA damage repair related genes in colorectal cancer. Shanghai J Traditional Chinese Med 2017,S1(51),181-184","journal-title":"Shanghai J Traditional Chinese Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/bcpt.13192","volume":"124","author":"Sarac S.B.","year":"2019","unstructured":"Sarac S.B.; Ainsworth M.A.; Hovgaard D.; Bjerrum O.W.; Progression-Free Survival (PFS) in oncology: Caveat emptor! Basic Clin Pharmacol Toxicol 2019,124(3),237-238","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"Chi K.N.","year":"2019","unstructured":"Chi K.N.; Agarwal N.; Bjartell A.; Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med TITAN Investigators2019,381(1),13-24","journal-title":"N Engl J Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Zhang Y.","year":"2019","unstructured":"Zhang Y.; Chen L.; Hu G.Q.; gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019,381(12),1124-1135","journal-title":"N Engl J Med"},{"key":"ref=39","author":"Jiang Q.","year":"2007","unstructured":"Jiang Q.; Clinical Epidemiology. ( 1st [39] ed.), Beijing: Higher Education Press 2007"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/jamaoncol.2018.5070","volume":"5","author":"Sherman S.K.","year":"2019","unstructured":"Sherman S.K.; Lange J.J.; Dahdaleh F.S.; Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer. JAMA Oncol 2019,5(2),236-242","journal-title":"JAMA Oncol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3736\/jcim20101009","volume":"8","author":"Liu N.N.","year":"2010","unstructured":"Liu N.N.; Zhou N.; Wang Y.; Chinese herbal medicine Jianpi Jiedu formula down-regulates the expression of vascular endothelial growth factor in human gastric cell line MKN45 induced by Helicobacter pylori by inhibiting cyclooxygenase-2. J Chin Integr Med 2010,8(10),968-973","journal-title":"J Chin Integr Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/cncr.26255","volume":"118","author":"Edeline J.","year":"2012","unstructured":"Edeline J.; Boucher E.; Rolland Y.; Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012,118(1),147-156","journal-title":"Cancer"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.11569\/wcjd.v12.i11.2701","volume":"12","author":"Wei B.","year":"2004","unstructured":"Wei B.; Chen Z.; Zhang W.; TCM syndrome score of gastrointestinal diseases. World Chin J Digestology 2004,12(11),2701-2703","journal-title":"World Chin J Digestology"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.21037\/atm.2018.02.12","volume":"6","author":"Zhang Z.","year":"2018","unstructured":"Zhang Z.; Reinikainen J.; Adeleke K.A.; Pieterse M.E.; Groothuis-Oudshoorn C.G.M.; Time-varying covariates and coefficients in Cox regression models. Ann Transl Med 2018,6(7),121","journal-title":"Ann Transl Med"},{"key":"ref=45","first-page":"1","volume":"6","author":"Abramson D.A.","year":"2020","unstructured":"Abramson D.A.; Resch Z.J.; Ovsiew G.P.; Impaired or invalid? Limitations of assessing performance validity using the Boston naming test. Appl Neuropsych-Adul 2020,6(9),1-6","journal-title":"Appl Neuropsych-Adul"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.soc.2012.07.009","volume":"21","author":"Sugarbaker P.H.","year":"2012","unstructured":"Sugarbaker P.H.; Early intervention for treatment and prevention of colorectal carcinomatosis: A plan for individualized care. Surg Oncol Clin N Am 2012,21(4),689-703","journal-title":"Surg Oncol Clin N Am"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0254-6272(13)60152-1","volume":"33","author":"Sun B.","year":"2013","unstructured":"Sun B.; Meng J.; Xiang T.; Jianpi Jiedu fang improves survival of hepatocarcinoma mice by affecting phosphatase and tensin homolog, phosphoinositide 3-kinase, and focal adhesion kinase. J Traditional Chinese 2013,33(4),479-485","journal-title":"J Traditional Chinese"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamaoncol.2020.0580","volume":"6","author":"Wang Z.X.","year":"2020","unstructured":"Wang Z.X.; Liang F.; Xu R.H.; The role of maintenance therapy in metastatic colorectal cancer. JAMA Oncol 2020,6(6),937","journal-title":"JAMA Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e194489","DOI":"10.1001\/jamaoncol.2020.0583","volume":"6","author":"Sonbol M.B.","year":"2020","unstructured":"Sonbol M.B.; Murad M.H.; Bekaii-Saab T.; The role of maintenance therapy in metastatic colorectal cancer-reply. JAMA Oncol 2020,6(3),e194489","journal-title":"JAMA Oncol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e000519","DOI":"10.1136\/esmoopen-2019-000519","volume":"4","author":"Cardone C.","year":"2019","unstructured":"Cardone C.; Martinelli E.; Troiani T.; Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a Phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. ESMO Open 2019,4(4),e000519","journal-title":"ESMO Open"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12876-018-0916-6","volume":"19","author":"Su J.","year":"2019","unstructured":"Su J.; Lai J.; Yang R.; Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: A retrospective analysis in Chinese postmenopausal women. BMC Gastroenterol 2019,19(1),17","journal-title":"BMC Gastroenterol"},{"key":"ref=52","first-page":"266","author":"Tang Z.","year":"1993","unstructured":"Tang Z.; Modern Oncology.: Shanghai Medical University Press: Shanghai, China 1993,266-274"},{"key":"ref=53","year":"1998","unstructured":"China Anticancer Association New Criteria of the Diagnosis and Treatment of Common Malignant Tumors-Fascicle of Colorectal Cancer. : China Union Medical University Press: Beijing, China 1998"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/annonc\/mdw101","volume":"27","author":"Luo H.Y.","year":"2016","unstructured":"Luo H.Y.; Li Y.H.; Wang W.; Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: Randomized clinical trial of efficacy and safety. Ann Oncol 2016,27(6),1074-1081","journal-title":"Ann Oncol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.15252\/emmm.201505492","volume":"7","author":"Deschoemaeker S.","year":"2015","unstructured":"Deschoemaeker S.; Di Conza G.; Lilla S.; PHD1 regulates p53-mediated colorectal cancer chemoresistance. EMBO Mol Med 2015,7(10),1350-1365","journal-title":"EMBO Mol Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3109\/03602532.2011.638303","volume":"44","author":"Marin J.J.","year":"2012","unstructured":"Marin J.J.; Sanchez de Medina F.; Casta\u00f1o B.; Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab Rev 2012,44(2),148-172","journal-title":"Drug Metab Rev"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"BSR20180641","DOI":"10.1042\/BSR20180641","volume":"2018","author":"Lin F.","year":"2018","unstructured":"Lin F.; Li H.; Wang J.; Wang F.; Efficacy and toxicities of combination maintenance therapy in the treatment of advanced colorectal cancer: A meta-analysis of randomized controlled trials. Biosci Rep 2018,2018,BSR20180641","journal-title":"Biosci Rep"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1016\/S2352-3026(18)30001-2","volume":"5","author":"Barr P.M.","year":"2018","unstructured":"Barr P.M.; Li H.; Burack W.R.; R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): A single-arm, Phase 2, multicentre study. Lancet Haematol 2018,5(3),e102-e108","journal-title":"Lancet Haematol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","volume":"385","author":"Simkens L.H.J.","year":"2015","unstructured":"Simkens L.H.J.; van Tinteren H.; May A.; Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015,385(9980),1843-1852","journal-title":"Lancet"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"e663","DOI":"10.1016\/j.clcc.2018.07.002","volume":"17","author":"Petrioli R.","year":"2018","unstructured":"Petrioli R.; Francini E.; Cherri S.; Capecitabine plus oxaliplatin and bevacizumab, followed by maintenance treatment with capecitabine and bevacizumab for patients aged > 75 years with metastatic colorectal cancer. Clin Colorectal Cancer 2018,17(4),e663-e669","journal-title":"Clin Colorectal Cancer"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"33418","DOI":"10.18632\/oncotarget.8644","volume":"7","author":"Zhao L.","year":"2016","unstructured":"Zhao L.; Wang J.; Li H.; Che J.; Cao B.; Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer. Oncotarget 2016,7(22),33418-33428","journal-title":"Oncotarget"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2014.10.019","volume":"51","author":"Ruff P.","year":"2015","unstructured":"Ruff P.; Ferry D.R.; Lakom\u1ef3 R.; Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur J Cancer 2015,51(1),18-26","journal-title":"Eur J Cancer"},{"key":"ref=63","first-page":"194","volume":"2","author":"Lai C-H.","year":"2015","unstructured":"Lai C-H.; Zhang J-L.; Zheng W-B.; Clinical value of S-1 capsule in the maintenance treatment of advanced metastatic colorectal cancer. Chin J Clin Oncol Rehabil 2015,2,194-196","journal-title":"Chin J Clin Oncol Rehabil"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e14326","DOI":"10.1097\/MD.0000000000014326","volume":"98","author":"Liu J.","year":"2019","unstructured":"Liu J.; Wang Y.; Jiang H.; Yu X.; Xu N.; Long-term survival of an elderly female with metastatic colon cancer after treated with capecitabine monotherapy: A case report. Medicine (Baltimore) 2019,98(5),e14326","journal-title":"Medicine (Baltimore)"},{"key":"ref=65","first-page":"2318","volume":"41","author":"Wei  Wang.","year":"2015","unstructured":"Wei Wang.; Wu Changping.; Sun Wenhui.; Efficacy of tegafur and capecitabine in the maintenance treatment of advanced colorectal cancer. Jiangsu Medical J 2015,41(19),2318-2319","journal-title":"Jiangsu Medical J"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1093\/annonc\/mdx122","volume":"28","author":"Kwakman J.J.M.","year":"2017","unstructured":"Kwakman J.J.M.; Simkens L.H.J.; van Rooijen J.M.; Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Ann Oncol 2017,28(6),1288-1293","journal-title":"Ann Oncol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.imr.2018.11.001","volume":"8","author":"Sui X.","year":"2019","unstructured":"Sui X.; Guo Y.; Ni W.; Jin H.; Lin H.; Xie T.; Molecular profiling analysis for colorectal cancer patients with Pi-Xu or Shi-Re syndrome. Integr Med Res 2019,8(1),21-25","journal-title":"Integr Med Res"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jtcm.2018.03.004","volume":"38","author":"Li Y.","year":"2018","unstructured":"Li Y.; Gu J.; Zhou H.; Traditional Chinese Medicine symptom patterns in patients with colorectal carcinoma. J Trad Chin Med 2018,38(2),299-308","journal-title":"J Trad Chin Med"},{"key":"ref=69","first-page":"323","volume":"19","author":"Jiang G","year":"2013","unstructured":"Jiang G; Zhang G; Dan RJCJETMF; Clinical curative effect observation of traditional Chinese and Western medicine combination for treatment of advanced colorectal cancer. J Exp Tradit Med Formulae 2013,19(12),323-5","journal-title":"J Exp Tradit Med Formulae"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2613198","DOI":"10.1155\/2017\/2613198","volume":"2017","author":"Liu X.","year":"2017","unstructured":"Liu X.; Ji Q.; Deng W.; JianPi JieDu recipe inhibits epithelial-to-mesenchymal transition in colorectal cancer through TGF-\u03b2\/Smad mediated Snail\/E-cadherin expression. BioMed Res Int 2017,2017,2613198","journal-title":"BioMed Res Int"},{"key":"ref=71","first-page":"686","volume":"38","author":"Yu K-N.","year":"2016","unstructured":"Yu K-N.; Ni Z-H.; Wang N-S.; A clinical multicenter randomized controlled study on Jianpi Qinghua decoction in treating stage 3 chronic kidney disease with a syndrome type of dampness-heat due to spleen deficiency. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2016,38(6),686-695","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"ref=72","first-page":"40","volume":"51","author":"Yang Y.","year":"2019","unstructured":"Yang Y.; Tang Y.; wanly Deng, Qi Li. Clinical study on the intervention effect of Jianpi Jiedu recipe on high risk population of colorectal cancer. Jiangsu Traditional Chinese Medicine 2019,51(1),40-42","journal-title":"Jiangsu Traditional Chinese Medicine"},{"key":"ref=73","first-page":"2090","volume":"30","author":"Zhang Y.","year":"2015","unstructured":"Zhang Y.; Xuan L.; Qing J.; Zhou L.; Clinical research on treating metastatic colorectal cancer with Jianpi Jiedu Decoction and chemotherapy. CJTCMP 2015,30(6),2090-2093","journal-title":"CJTCMP"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11655-008-0251-9","volume":"14","author":"Yang Y.F.","year":"2008","unstructured":"Yang Y.F.; Ge J.Z.; Wu Y.; Cohort study on the effect of a combined treatment of traditional Chinese medicine and Western medicine on the relapse and metastasis of 222 patients with stage II and III colorectal cancer after radical operation. Chin J Integr Med 2008,14(4),251-256","journal-title":"Chin J Integr Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"e000361","DOI":"10.1136\/bmjgast-2019-000361","volume":"7","author":"Klepp P.","year":"2020","unstructured":"Klepp P.; Brackmann S.; Cvancarova M.; Risk of colorectal cancer in a population-based study 20 years after diagnosis of ulcerative colitis: Results from the IBSEN study. BMJ Open Gastroenterol 2020,7(1),e000361","journal-title":"BMJ Open Gastroenterol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/j.clcc.2016.09.010","volume":"16","author":"Sunakawa Y.","year":"2017","unstructured":"Sunakawa Y.; Ichikawa W.; Tsuji A.; Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: A subgroup analysis of the JACCRO CC-05\/06 trials. Clin Colorectal Cancer 2017,16(3),e171-e180","journal-title":"Clin Colorectal Cancer"},{"key":"ref=77","first-page":"2","author":"Zhang Y.","year":"2010","unstructured":"Zhang Y.; Xu J.H.; Sun J.;  Clinical study of Jianpijiedu-Decoction plus FOLFOX4 regimen in the treatment of advanced colorectal cancer  Global Traditional Chinese Medicine 2010,2","journal-title":"Clinical study of Jianpijiedu-Decoction plus FOLFOX4 regimen in the treatment of advanced colorectal cancer  Global Traditional Chinese Medicine"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/jso.24774","volume":"116","author":"Mahar A.L.","year":"2017","unstructured":"Mahar A.L.; Compton C.; Halabi S.; Hess K.R.; Weiser M.R.; Groome P.A.; Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes. J Surg Oncol 2017,116(8),969-982","journal-title":"J Surg Oncol"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ejca.2015.03.015","volume":"51","author":"Brule SY","year":"2015","unstructured":"Brule SY; Jonker DJ; Karapetis CS; Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer (Oxford, England: 1990) 2015,51(11),1405-14","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1089\/acm.2018.0125","volume":"24","author":"Block K.I.","year":"2018","unstructured":"Block K.I.; Block P.B.; Gyllenhaal C.; Integrative treatment for colorectal cancer: A comprehensive approach. J Altern Complement Med 2018,24(9-10),890-901","journal-title":"J Altern Complement Med"}],"container-title":["Recent Patents on Anti-Cancer Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/183830","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183830\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/183830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T16:52:49Z","timestamp":1632502369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183830\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,12,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574892815666200717141205","relation":{},"ISSN":["1574-8928"],"issn-type":[{"value":"1574-8928","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}